High blood pressure linked to reduced Alzheimer’s risk, meds may be reason
A new study suggests that people with a genetic predisposition to high blood pressure have a lower risk for Alzheimer’s disease.
A new study suggests that people with a genetic predisposition to high blood pressure have a lower risk for Alzheimer’s disease.
A new study suggests that people with a genetic predisposition to high blood pressure have a lower risk for Alzheimer’s disease.
by Bruce Sylvester: Menopausal women having difficulty with time management, attention, organization, memory, and problem solving (also known as “executive functions”) appear to benefit from treatment with lisdexamfetamine,… read more.
by Bruce Sylvester: Treatment with tofacitinib, a drug for rheumatoid arthritis, has restored skin color in a patient suffering from vitiligo, researchers reported on June 24 in JAMA… read more.
by Bruce Sylvester: A study of the protective effect of heart medications that patients receive before coronary artery bypass graft (CABG) surgery suggests that statins reduce the risk… read more.
by Bruce Sylvester: Rociletinib, an investigative therapy for treatment resistant EGFR-mutation driven lung tumors, shows activity against the most common resistance mutation, and it significantly improves clinical outcomes.
by Gary Finnegan: A new study has revealed a number of factors that appear to predict a child’s risk of developing ankylosing spondylitis (AS).
by Gary Finnegan: Peanut and nut intake appear to lower mortality rates from major diseases, according to a new study, but peanut butter has no shown any protective… read more.
by Gary Finnegan: People with terminal cancer often require palliative care in the late stages of their lives. This branch of medicine has long been lauded for the… read more.
by Gary Finnegan: Rapid weight loss can lead to a loss of bone mass and an increased risk of bone fractures. A study by University of Copenhagen, Hvidovre… read more.
by Gary Finnegan: Keytruda (pembrolizumab) has been recommended by the European Medicines Agency (EMA) as monotherapy for the treatment of adult patients with advanced melanoma that cannot be… read more.
by Gary Finnegan: Survival rates in young patients with high-risk neuroblastoma can be improved by Unituxin (dinutuximab), a new treatment approved by the European Medicines Agency (EMA).
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.